2 results
Approved WMOPending
To evaluate the efficacy and safety of extended release (ER) Niacin/Laropiprant when added to ongoing lipid-modifying therapy in patients with primary hypercholesterolemia or mixed dyslipidemia.
Approved WMOCompleted
To evaluate the utility of the WATS system, as a potential substitute for the random sampling method that is currently recommended as an adjunct to targeted biopsy